A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This open-label, Phase 1 study will investigate the 5-hydroxytryptamine 6 (5-HT6) receptor
occupancy in the brain using positron emission tomography (PET) following single oral doses
of SLV354. Up to 22 healthy male subjects and male subjects with stable schizophrenia,
between 18-55 years of age are to complete the study.